Wuhan Institute of Biological Products Co., Ltd.
Establishment time : 1967
website : http://www.wibp.com.cn/
Main Product : vaccines, biological products
Company Profile
Wuhan Institute of Biological Products Co., Ltd. is a renowned biopharmaceutical company established in 1967. It specializes in the research, development, and production of vaccines and biological products. With a large company size, it is a key player in the Chinese market and has also expanded its presence in international markets. Despite facing competition from other global pharmaceutical companies, the company continues to innovate and deliver high-quality products to meet the healthcare needs of people worldwide.
Chengdu Institute of Biological Products Co., Ltd.
Establishment time : 1958
website : http://www.cibp.com.cn/
Main Product : Vaccines, biological products
Company Profile
Chengdu Institute of Biological Products Co., Ltd. is a renowned company established in 1958, specializing in the production of vaccines and biological products. With a large company size, they are a leading manufacturer in China and have a strong presence in both domestic and international markets. Visit their website for more information: http://www.cibp.com.cn/
Changchun Institute of Biological Products Co., Ltd.
Establishment time : 1941
website : http://www.cibp.cnic.cn/
Main Product : Vaccines, biological products
Company Profile
Changchun Institute of Biological Products Co., Ltd. is a leading biopharmaceutical company in China, specializing in the research, development, and production of vaccines and biological products. With a history dating back to 1941, the company has grown to become a key player in the global healthcare industry. They have a strong presence in both the domestic and international markets, offering a wide range of high-quality products to meet the needs of customers worldwide.
Sinovac Biotech Co., Ltd.
Establishment time : 2001
website : www.sinovac.com
Main Product : Vaccines for infectious diseases such as influenza, hepatitis, and COVID-19
Company Profile
Sinovac Biotech Co., Ltd. is a leading biopharmaceutical company in China, specializing in the research, development, production, and commercialization of vaccines for various infectious diseases. With a focus on innovation and quality, Sinovac has established itself as a key player in the global vaccine market.
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Establishment time : 2002
website : www.tianyuanpharm.com
Main Product : Heparin Sodium, Enoxaparin Sodium, Fondaparinux Sodium
Company Profile
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. is a leading pharmaceutical company specializing in the production of anticoagulant drugs. Established in 2002, the company has a strong presence in both domestic and international markets, offering a range of high-quality products such as Heparin Sodium, Enoxaparin Sodium, and Fondaparinux Sodium. With a medium-sized company size, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. faces competition from other pharmaceutical companies but continues to maintain its position as a key player in the industry. Visit their website at www.tianyuanpharm.com for more information.
Liaoning Chengda Biotechnology Co., Ltd.
Establishment time : 2001
website : www.lncdbio.com
Main Product : Probiotics, enzymes, feed additives
Company Profile
Liaoning Chengda Biotechnology Co., Ltd. is a leading biotechnology company specializing in the production of probiotics, enzymes, and feed additives. Founded in 2001, the company has grown to become a key player in the industry, serving markets in China, Southeast Asia, and South America. With a focus on quality and innovation, Chengda Biotechnology continues to drive advancements in biotechnology for the agricultural sector.
Changchun Zhuoyi Biological Co., Ltd
Company Profile
Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.
Shenzhen Kangtai Biological Products Co., Ltd.
Establishment time : Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992.
website : http://www.kangtaibio.com/
Main Product : Kangtai specializes in the production of vaccines, blood products, and diagnostic reagents.
Company Profile
Kangtai is committed to improving public health through the development of advanced biopharmaceutical products.
Changchun BCHT Biotechnology Co., Ltd.
Establishment time : August 2003
website : www.bchtpeptide.com
Main Product : Peptide products for research and industrial use
Company Profile
Changchun BCHT Biotechnology Co., Ltd. was founded in August 2003 and has since become a trusted provider of peptide products for research and industrial applications. With a focus on quality and customer satisfaction, BCHT Biotechnology Co., Ltd. has established itself as a key player in the global peptide market.
Beijing Tiantan Biological Products Co., Ltd.
Establishment time : Beijing Tiantan Biological Products Co., Ltd. was founded in 1992.
website :
Main Product : With a large company size, Beijing Tiantan is a key player in the industry.
Company Profile
Beijing Tiantan is committed to improving public health through its products and research efforts.
June 11, 2024
